Talaris Therapeutics, Inc. TALS
We take great care to ensure that the data presented and summarized in this overview for Talaris Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TALS
Top Purchases
Top Sells
About TALS
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Insider Transactions at TALS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2025
|
Sandeep Chidambar Kulkarni CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
7,000
-100.0%
|
-
|
|
Oct 28
2025
|
Sandeep Chidambar Kulkarni CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,387
-100.0%
|
-
|
|
Oct 28
2025
|
Sandeep Chidambar Kulkarni CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
724,664
-95.98%
|
-
|
|
Oct 28
2025
|
Ryan F. Robinson CFO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,366
-100.0%
|
-
|
|
Oct 28
2025
|
W Bradford Middlekauff CBO, GC and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,213
-100.0%
|
-
|
|
Oct 28
2025
|
W Bradford Middlekauff CBO, GC and Secretary |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
60,988
-88.13%
|
-
|
|
Oct 28
2025
|
Susan Dana Jones Chief Technology Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,152
-100.0%
|
-
|
|
Oct 28
2025
|
Susan Dana Jones Chief Technology Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
19,782
-86.26%
|
-
|
|
Oct 28
2025
|
Kevin Bruce Johnson Chief Regulatory Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,046
-100.0%
|
-
|
|
Oct 28
2025
|
Kevin Bruce Johnson Chief Regulatory Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
40,538
-78.59%
|
-
|
|
Oct 28
2025
|
Caley Castelein |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
431,939
-100.0%
|
-
|
|
Oct 28
2025
|
Caley Castelein |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
515,997
-100.0%
|
-
|
|
Oct 28
2025
|
Aaron Kantoff |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
88,281
-100.0%
|
-
|
|
Oct 28
2025
|
Mark Mcdade |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
741,691
-100.0%
|
-
|
|
Oct 28
2025
|
Mark Mcdade |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
518
-100.0%
|
-
|
|
Oct 28
2025
|
Sapna Srivastava |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
518
-100.0%
|
-
|
|
Oct 28
2025
|
Parvinder Thiara |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
83,782
-100.0%
|
-
|
|
Oct 24
2025
|
Aaron Kantoff |
SELL
Bona fide gift
|
Direct |
5,000
-5.36%
|
-
|
|
Oct 22
2025
|
Sandeep Chidambar Kulkarni CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,316
+3.24%
|
$177,212
$7.9 P/Share
|
|
Oct 22
2025
|
Ryan F. Robinson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,366
+50.0%
|
$186,758
$13.92 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 87.6K shares |
|---|
| Bona fide gift | 11.8K shares |
|---|---|
| Disposition due to a tender of shares in a change of control transaction | 2.73M shares |
| Sale (or disposition) back to the issuer | 52.8K shares |